NR2C2 Polyclonal Antibody, AbBy Fluor™ 594 Conjugated

Product Specifications

Background

Orphan nuclear receptor that can act as a repressor or activator of transcription. An important repressor of nuclear receptor signaling pathways such as retinoic acid receptor, retinoid X, vitamin D3 receptor, thyroid hormone receptor and estrogen receptor pathways. May regulate gene expression during the late phase of spermatogenesis. Together with NR2C1, forms the core of the DRED (direct repeat erythroid-definitive) complex that represses embryonic and fetal globin transcription including that of GATA1. Binds to hormone response elements (HREs) consisting of two 5'-AGGTCA-3' half site direct repeat consensus sequences. Plays a fundamental role in early embryonic development and embryonic stem cells. Required for normal spermatogenesis and cerebellum development. Appears to be important for neurodevelopmentally regulated behavior (By similarity) . Activates transcriptional activity of LHCG. Antagonist of PPARA-mediated transactivation.

Synonyms

TR4; TAK1; Nuclear receptor subfamily 2 group C member 2; Orphan nuclear receptor TAK1; Orphan nuclear receptor TR4; Testicular receptor 4; NR2C2

Gene ID

7182

Swiss Prot

P49116

Cellular Locus

Nucleus

Host

Rabbit

Cross Reactivity

Mouse

Immunogen

501-596/596

Target

NR2C2

Clonality

Polyclonal

Isotype

IgG

Conjugation

AbBy Fluor™ 594

Source

KLH conjugated synthetic peptide derived from human NR2C2/TAK1

Applications

IF (IHC-P), IF (IHC-F), IF (ICC)

Purification

Purified by Protein A.

Excitation Emission

590nm/617nm

Concentration

1µg/µl

Dilution

IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Buffer

Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Modification

Unmodified

Storage Conditions

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Specificity

This antibody may have a minor secondary cross-reactivity towards NR2C1 in human and rat, based upon a non-sequential 77% sequence similarity over the immunogen range.